61. Gatti -Mays, M.E., et al., A Phase 1 Dose Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clin Cancer Res, 2019. May 20. pii: clincanres.0183.2019. doi: 10.1158/1078-0432.CCR-19-0183. [Epub ahead of print] . 62. Horn, L.A., et al., Simultaneous inhibition of CXCR1/2, TGF- β, and PD -L1 remodels the tumor and its microenvironment to drive antitumor immunity. J Immunother Cancer, 2020. 8(1). 63. G atti-Mays, M., et al. , A Phase I Trial Using A Multi -Targeted Recombinant Ad5 (CEA/MUC/Brach yury) -based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. 2019, The Oncologist.